Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IBI 324

X
Drug Profile

IBI 324

Alternative Names: IBI-324

Latest Information Update: 07 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovent Biologics
  • Class Anti-inflammatories; Bispecific antibodies; Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diabetic macular oedema

Most Recent Events

  • 06 Nov 2023 Efficacy and adverse event data from a phase I trial in Age-related macular degeneration released by Innovent Biologics
  • 05 Jun 2023 Innovent Biologics completes a phase I trial in Diabetic macular edema in China (NCT05489718)
  • 07 Aug 2022 Phase-I clinical trials in Diabetic macular oedema (In adults, In the elderly) in China (Intravitreous) (9365051; NCT05489718)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top